Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy

Alexis D. Leal,Kunal C. Kadakia,Sherry A. Looker,Crystal R. Hilger,Kristine Sorgatz,Kari J. Anderson,A. Jacobson,Darryl C. Grendahl,Drew K. Seisler,Timothy James Hobday,Charles Lawrence Loprinzi

Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy

2014

Alexis D. Leal
Kunal C. Kadakia
Sherry A. Looker
Crystal R. Hilger
Kristine Sorgatz
Kari J. Anderson
A. Jacobson
Darryl C. Grendahl
Drew K. Seisler
Timothy James Hobday
Charles Lawrence Loprinzi

Purpose The purpose of this study was to investigate the incidence of fosaprepitant-associated infusion site adverse events (ISAEs) among a cohort of breast cancer patients receiving doxorubicin/cyclophosphamide (AC) chemotherapy.

Keywords:

Breast cancer
Intensive care medicine
Doxorubicin
Retrospective cohort study
Fosaprepitant
Medicine
Cyclophosphamide
Adverse effect
Chemotherapy-induced nausea and vomiting
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations